Important Differences in Cancer Care

  • Gregory L. Hall


African Americans have the highest mortality for the top five causes of cancer death. The reasons for these and other cancer disparities are not easily explained, but a better understanding of current hypotheses and best practices may improve your patient’s outcomes. A study of almost 20,000 cancer patients found that “when controlled for uniform stage, treatment, and follow up, African American sex-specific cancers (breast, ovarian, and prostate) still did worse.” The colon cancer incidence and death rate is so high in the African American community that the American College of Gastroenterology recommends screening begin at age 45. Studies also showed an increased occurrence in African Americans for right-sided colon cancer tumors prompting recommendations against sigmoidoscopy in these patients because a majority of tumors would be missed. Prostate cancer in African American men is the most prevalent occurring cancer, and the second most common cause of overall cancer deaths. European American male smokers consume 30%–40% more cigarettes than their African American counterparts, but African American male smokers are 34% more likely to develop lung cancer. These and other curious cancer differences are more closely examined.


  1. 1.
    QuickStats: age-adjusted death rates for top five causes of cancer death, by Race/Hispanic Ethnicity — United States. MMWR Morb Mortal Wkly Rep. 2016;65:989.
  2. 2.
    Centers for Disease Control and Prevention. Breast cancer rates among black and white women.
  3. 3.
    American Cancer Society. Breast cancer facts & figures 2017–2018. Atlanta: American Cancer Society, Inc; 2017.Google Scholar
  4. 4.
    Albain K, Unger J, Crowley J, Coltman C, Hershman D. Racial disparities in cancer survival among randomized clinical trials patients of the southwest oncology group. J Natl Cancer Inst. 2009;101(14):984–92.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Newman L, Stark A, Chitale D, et al. Association between benign breast disease in African American and white American women and subsequent triple-negative breast Cancer. JAMA Oncol. 2017;3(8):1102–6.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Bazargan M, Lucas-Wright A, Jones L, et al. Understanding perceived benefit of early cancer detection: community-partnered research with African American women in South Los Angeles. J Women’s Health (Larchmt). 2015;24(9):755–61.Google Scholar
  7. 7.
    Ananthakrishnan A, Schellhase K, Sparapani R, Laud P, Neuner J. Disparities in colon cancer screening in the Medicare population. Arch Intern Med. 2007;167(3):258–64.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Rex D, Johnson D, Anderson J, et al. Colorectal cancer screening. Am J Gastroenterol. 2009;104:739–50.Google Scholar
  9. 9.
    Paquette I, Ying J, Shah S, Abbott D, Ho S. African Americans should be screened at an earlier age for colorectal cancer. Gastrointest Endosc. 2015;82(5):878–83.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Chattar-Cora D, Onime G, Valentine I, Cudjoe E, Rivera L. Colorectal cancer in a multi-ethnic urban group: its anatomical and age profile. Int Surg. 2000;85(2):137–42.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Fedewa S, Flanders W, Ward K, et al. Racial and ethnic disparities in interval colorectal cancer incidence: a population-based cohort study. Ann Intern Med. 2017;166(12):857–66.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Myers R, Sifri R, Daskalakis C, et al. Increasing colon cancer screening in primary care among African Americans. J Natl Cancer Inst. 2014;106(12):dju344.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Myers R, Bittner-Fagan H, Daskalakis C, et al. A randomized controlled trial of a tailored navigation and a standard intervention in colorectal cancer screening. Cancer Epidemiol Biomark Prev. 2013;22(1):109–17.Google Scholar
  14. 14.
    Rawl S, Skinner C, Perkins S, et al. Computer-delivered tailored intervention improves colon cancer screening knowledge and health beliefs of African Americans. Health Educ Res. 2012;27(5):868–85.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Jerant A, Sohler N, Fiscella K, et al. Tailored interactive multimedia computer programs to reduce health disparities: opportunities and challenges. Patient Edu Couns. 2011;85:323–30.Google Scholar
  16. 16.
    U.S. Preventative Services Task Force. Published final recommendations. Accessed 9 May 2019.
  17. 17.
    Shenoy D, Packiananthan S, Chen A, Vijayakumar S. Do African American men need separate prostate cancer screening guidelines? BMC Urol. 2016;16:19.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Vastag B. Government task force discourages routine testing for prostate cancer. The Washington Post., 21 May 2012. Accessed 9 May 2019.
  19. 19.
    Carter H, Albertsen P, Barry M, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190(2):419–26.PubMedPubMedCentralGoogle Scholar
  20. 20.
    US Preventative Services Task Force, Grossman DC, Curry SJ, et al. Screening for prostate cancer: US Preventative Services Task Force recommendation statement. JAMA. 2018;319(18):1901–13.Google Scholar
  21. 21.
    Lathan C, Waldman BE, Gagne J, Emmons K. Perspectives of African Americans on lung cancer: a qualitative analysis. Oncologist. 2015;20(4):393–9.PubMedPubMedCentralGoogle Scholar
  22. 22.
    American Cancer Society. Cancer facts & figures for African Americans 2016–2018. Atlanta: American Cancer Society, Inc; 2016.Google Scholar
  23. 23.
    Ryan B. Lung cancer health disparities. Carcinogenesis. 2018;39(6):741–51.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Tran H, et al. Predictors of lung cancer: noteworthy cell type differences. Perm J. 2013;17:23–9.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Luo J, et al. Environmental carcinogen releases and lung cancer mortality in rural-urban areas of the United States. J Rural Health. 2011;27:342–9.Google Scholar
  26. 26.
    Katki H, Kovalchik S, Berg C, Cheung L, Chaturvedi A. Development and validation of risk models to select ever-smokers for CT lung cancer screening. JAMA. 2016;315(21):2300–11.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Stead L, Buitrago S, Preciado N, et al. Does advice from doctors encourage people who smoke to quit. Cochrane.
  28. 28.
    Dhumal G, Pednekar M, Gupta P, et al. Quit history, intentions to quit, and reasons for considering quitting among tobacco users in India: findings from the wave 1 TCP India survey. Indian J Cancer. 2014;51(01):S39–45.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Danesh D, Paskett E, Ferketich A. Disparities in receipt of advice to quit smoking from health care providers: 2010 National Health Interview Survey. Prev Chronic Dis. 2014;11:e131.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Soulakova J, Li J, Crockett L. Race/ethnicity and intention to quit cigarette smoking. Prev Med Rep. 2017;5:160–5.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Kulak J, Cornelius M, Fong G, Giovino G. Differences in quit attempts and cigarette smoking abstinence between whites and African Americans in the United States: literature review and results from the International Tobacco Control US Survey. Nicotine Tob Res. 2016;18(Suppl 1):S79–87.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Alexander L, Trinidad D, Sakuma K, et al. Why we must continue to investigate menthol’s role in the African American smoking paradox. Nicotine Tob Res. 2016;18(Suppl 1):S91–101.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Gandhi K, Foulds J, Steinberg M, Lu S, Williams J. Lower quit rates among African Americans and Latino menthol cigarette smokers at a tobacco treatment clinic. Int J Clin Pract. 2009;63(3):360–7.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Delnevo CD, Gundersen DA, Hrywna M, et al. Smoking-cessation prevalence among U.S. smokers of menthol versus non-menthol cigarettes. Am J Prev Med. 2011;41:357–65.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Nonnemaker J, Hersey J, Homsi G, et al. Initiation with menthol cigarettes and youth smoking uptake. Addiction. 2013;108:171–8.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Henriksen L, Schleicher NC, Dauphinee AL, et al. Targeted advertising, promotion, and price for menthol cigarettes in California high school neighborhoods. Nicotine Tob Res. 2012;14:116–21.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Moreland-Russell S, Harris J, Snider D, et al. Disparities and menthol marketing: additional evidence in support of point of sale policies. Int J Environ Res Public Health. 2013;10:4571–83.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Greenberg AJ, Vachon CM, Rajkumar SV. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia. 2012;26(4):609–14.Google Scholar
  39. 39.
    Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010;116:5501–6. Scholar
  40. 40.
    Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012;119(9):2100–5.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Greenberg AJ, Philip S, Paner A, et al. Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study. Blood Cancer J. 2015;5:e271. Scholar
  42. 42.
    Landgren O, Rajkumar SV, Pfeiffer RM, et al. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance (MGUS) among African American and Caucasian women. Blood. 2010;116(7):1056–9.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Costa LJ, Huang JX, Hari PN. Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. Biol Blood Marrow Transplant. 2015;21(4):701–706.v.Google Scholar
  44. 44.
    Hari PN, Majhail NS, Zhang MJ, et al. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2010;16:395–402.Google Scholar
  45. 45.
    Joshua TV, Rizzo JD, Zhang MJ, et al. Access to hematopoietic stem cell transplantation: effect of race and sex. Cancer. 2010;116:3469–76.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Al-Hamadani M, Hashmi SK, Go RS. Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents. Am J Hematol. 2014;89:825.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Fiala MA, Wildes TM. Racial disparities in treatment use for multiple myeloma. Cancer. 2017;123:1590–6.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Biagi JJ, Raphael M, King WD, et al. The effect of delay in time to adjuvant chemotherapy (TTAC) on survival in breast cancer (BC): a systematic review and meta-analysis. ASCO Meet Abstr. 2011;29(15_suppl):1128.Google Scholar
  49. 49.
    Colleoni M, Bonetti M, Coates AS, The International Breast Cancer Study Group, et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. J Clin Oncol. 2000;18(3):584–90.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Kim YW, Choi EH, Kim BR, et al. The impact of delayed commencement of adjuvant chemotherapy (eight or more weeks) on survival in stage II and III colon cancer: a national population-based cohort study. Oncotarget. 2017;8(45):80061–72.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Salazar MC, Rosen JE, Wang Z, et al. Association of delayed adjuvant chemotherapy with survival after lung cancer surgery. JAMA Oncol. 2017;3(5):610–9.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Petrelli F, Zaniboni A, Ghidini A, et al. Timing of adjuvant chemotherapy and survival in colorectal, gastric, and pancreatic cancer. A systemic review and meta-analysis. Cancers (Basel). 2019;11(4):Pii: E550. Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Gregory L. Hall
    • 1
  1. 1.Partnerships for Urban HealthCleveland State UniversityClevelandUSA

Personalised recommendations